<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662511"><TermName>gemcitabine-erlotinib regimen</TermName><TermPronunciation>(jem-SY-tuh-been-er-LOH-tih-nib REH-jih-men)</TermPronunciation><TermDefinition><DefinitionText>A chemotherapy combination used for the treatment of locally advanced and metastatic pancreatic cancer. It includes the drugs gemcitabine hydrochloride and erlotinib hydrochloride. Also called gemcitabine-Tarceva regimen.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725970" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;gemcitabine-erlotinib regimen&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725971" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen gemcitabina-erlotinib&quot;" language="es" id="_4"/><SpanishTermName>régimen gemcitabina-erlotinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Quimioterapia combinada que se usa para el cáncer de páncreas metastásico localmente avanzado. Incluye los medicamentos clorhidrato de gemcitabina y clorhidrato de erlotinib. También se llama régimen gemcitabina-Tarceva.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-05-26</DateFirstPublished><DateLastModified>2012-09-06</DateLastModified></GlossaryTerm>
